SARS-CoV-2 奥密克戎变异株 BA.2.87.1 的中和作用。
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
机构信息
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
出版信息
Vaccine. 2024 Apr 2;42(9):2117-2121. doi: 10.1016/j.vaccine.2024.03.007. Epub 2024 Mar 7.
A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared with BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple mutations in BA.2.87.1 are located in the N-terminal domain (NTD) rather than in the receptor binding domain (RBD) of the Spike protein. We evaluated neutralizing antibody (NAb) responses to BA.2.87.1 because of its highly mutated sequence and its unique NTD region. Our data show that NAb responses to BA.2.87.1 were lower than to BA.2 but higher than to JN.1, suggesting that BA.2.87.1 is not a further antibody escape variant compared with other currently circulating variants. Moreover, XBB.1.5 mRNA boosting increased NAb titers to all variants tested including BA.2.87.1.
一种新的高度突变的奥密克戎亚变体 BA.2.87.1 最近被发现，与 BA.2、BA.5、XBB.1.5 和 JN.1 变体相比，其 Spike 蛋白中有超过 30 个氨基酸突变。BA.2.87.1 的多个突变位于 Spike 蛋白的 N 端结构域（NTD），而不是受体结合域（RBD）。由于其高度突变的序列及其独特的 NTD 区域，我们评估了针对 BA.2.87.1 的中和抗体（NAb）反应。我们的数据表明，针对 BA.2.87.1 的 NAb 反应低于针对 BA.2 的反应，但高于针对 JN.1 的反应，这表明与其他目前流行的变体相比，BA.2.87.1 不是进一步的抗体逃逸变体。此外，XBB.1.5 mRNA 增强剂增加了针对所有测试变体（包括 BA.2.87.1）的 NAb 滴度。
Zotero 插件